Slide 1: Quarterly Update
For personal use only ™ Quarterly Update Gary Phillips, CEO 1st August 2025
Slide 2: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 3: Highlights
Highlights • Amsulostat builds momentum: • The WHO grants the International Non-Proprietary Name (INN) of amsulostat to SNT-5505 For personal use only • FDA Fast Track designation received for amsulostat for the treatment of myelofibrosis • Positive interim Phase 2 clinical data for amsulostat prese
Slide 4: Myelofibrosis phase study interim data conclusions
Myelofibrosis phase 2 study interim data conclusions Interim data1 suggests that amsulostat combined with ruxolitinib may deliver deep and long-lasting benefit to patients who are sub-optimally controlled on ruxolitinib alone For personal use only Consistent with Despite the relatively Reductions in
Slide 5: Targeting Multiple Near Term Opportunities in High Value Markets
Targeting Multiple Near Term Opportunities in High Value Markets Anticipated Upcoming Addressable market For personal use only Drug Candidate Indication Phase Milestones (US$) Interim 12 month data Myelofibrosis Phase 2 ~$1 billion1 June 2025 Amsulostat Myelodysplastic Syndrome Low & intermediate Ri
Slide 6: Recent & Anticipated News Flow
Recent & Anticipated News Flow Strong and growing pipeline with advancement in studies expected to provide value inflection points For personal use only COMPLETED Q1 2025 June 2025 Q2 2025 Mid 2025 Key Events Q3 25 Q4 2024 SNT-5505 Phase 2a Syntara skin • FDA grants Fast Track FDA commence SNT-5505
Slide 7: Gary Phillips, Chief Executive Officer
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au www.syntaraTX.com.au